Online inquiry

IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ8413MR)

This product GTTS-WQ8413MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets HSP90 gene. The antibody can be applied in Candidiasis research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	XP_721353.1
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3636951
UniProt ID	P46598

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8413MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ11810MR	IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	MK-3475
GTTS-WQ15138MR	IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	SYNT-001
GTTS-WQ4206MR	IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	BIIB019
GTTS-WQ14651MR	IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	SC-003 mAb
GTTS-WQ886MR	IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	ABBV-181
GTTS-WQ14206MR	IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	RG4934
GTTS-WQ8264MR	IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	HLX10
GTTS-WQ3008MR	IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	Angiocept

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST